Literature DB >> 11477410

CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein.

R A Tripp1, L P Jones, L M Haynes, H Zheng, P M Murphy, L J Anderson.   

Abstract

Chemokines are chemoattractant proteins that are divided into subfamilies based upon cysteine signature motifs termed C, CC, CXC and CX3C. Chemokines have roles in immunity and inflammation that affect cell trafficking and activation of T cells as well as cells of the innate immune system. We report here CX3C chemokine mimicry for the G glycoprotein of respiratory syncytial virus (RSV) and show binding to CX3CR1--the specific receptor for the CX3C chemokine fractalkine--and induction of leukocyte chemotaxis. We also show that CX3CR1 facilitates RSV infection of cells. Thus, G glycoprotein interaction with CX3CR1 probably plays a key role in the biology of RSV infection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477410     DOI: 10.1038/90675

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  167 in total

1.  The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.

Authors:  Michael N Teng; Peter L Collins
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 3.  Microglia in Health and Disease.

Authors:  Richard M Ransohoff; Joseph El Khoury
Journal:  Cold Spring Harb Perspect Biol       Date:  2015-09-09       Impact factor: 10.005

4.  Respiratory syncytial virus(RSV)-induced allergy may be controlled by IL-4 and CX3C fractalkine antagonists and CpG ODN as adjuvant: hypothesis and implications for treatment.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

5.  Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.

Authors:  Junyan Han; Katsuyuki Takeda; Meiqin Wang; Wanjiang Zeng; Yi Jia; Yoshiki Shiraishi; Masakazu Okamoto; Azzeddine Dakhama; Erwin W Gelfand
Journal:  Am J Respir Cell Mol Biol       Date:  2014-07       Impact factor: 6.914

Review 6.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 7.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 8.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 9.  Molecular mechanisms driving respiratory syncytial virus assembly.

Authors:  Fyza Y Shaikh; James E Crowe
Journal:  Future Microbiol       Date:  2013-01       Impact factor: 3.165

10.  RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response.

Authors:  Wenliang Zhang; Ralph A Tripp
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.